Ventyx Biosciences Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Ventyx Biosciences wird ein Gewinn- und Umsatzwachstum von 5.9% bzw. 67.9% pro Jahr prognostiziert, während der Gewinn pro Aktie um 20.9% pro Jahr wachsen soll.

Wichtige Informationen

5.9%

Wachstumsrate der Gewinne

20.9%

EPS-Wachstumsrate

Pharmaceuticals Gewinnwachstum	23.7%
Wachstumsrate der Einnahmen	67.9%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Good
Zuletzt aktualisiert	15 Oct 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Companies Like Ventyx Biosciences (NASDAQ:VTYX) Are In A Position To Invest In Growth

Sep 21

Ventyx Biosciences (NASDAQ:VTYX) Is In A Good Position To Deliver On Growth Plans

Jun 07

We're Not Very Worried About Ventyx Biosciences' (NASDAQ:VTYX) Cash Burn Rate

Feb 20

Ventyx Biosciences: Not Chasing This Rally

Sep 18

We Think Ventyx Biosciences (NASDAQ:VTYX) Can Afford To Drive Business Growth

Aug 19

Ventyx Biosciences GAAP EPS of -$0.39 beats by $0.06

Aug 15

Ventyx Biosciences autoimmune/autoinflammatory candidate meets phase 1 goals

Jun 29

We're Not Very Worried About Ventyx Biosciences' (NASDAQ:VTYX) Cash Burn Rate

May 06

We Think Ventyx Biosciences (NASDAQ:VTYX) Can Afford To Drive Business Growth

Jan 21

Gewinn- und Umsatzwachstumsprognosen

NasdaqGS:VTYX - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	67	-151	-146	-165	5
12/31/2025	N/A	-178	-141	-163	7
12/31/2024	N/A	-148	-136	-144	7
6/30/2024	N/A	-171	-159	-158	N/A
3/31/2024	N/A	-193	-184	-183	N/A
12/31/2023	N/A	-193	-167	-167	N/A
9/30/2023	N/A	-181	-163	-162	N/A
6/30/2023	N/A	-158	-152	-151	N/A
3/31/2023	N/A	-125	-117	-117	N/A
12/31/2022	N/A	-108	-99	-99	N/A
9/30/2022	N/A	-91	-66	-66	N/A
6/30/2022	N/A	-73	-54	-53	N/A
3/31/2022	N/A	-69	-49	-48	N/A
12/31/2021	N/A	-85	-39	-39	N/A
9/30/2021	N/A	-84	-26	-26	N/A
6/30/2021	N/A	-79	-17	-17	N/A
3/31/2021	N/A	-65	-8	-8	N/A
12/31/2020	N/A	-28	-6	-6	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: VTYX wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: VTYX wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: VTYX wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: VTYX wird im nächsten Jahr voraussichtlich keine Einnahmen haben.

Hohe Wachstumseinnahmen: VTYX wird im nächsten Jahr voraussichtlich keine Einnahmen haben.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von VTYX in 3 Jahren voraussichtlich hoch sein wird

Ventyx Biosciences Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target decreased by 10.0% to US$10.00

Price target increased by 9.8% to US$11.75

Price target increased by 13% to US$10.90

Price target increased by 8.9% to US$9.67

Price target decreased by 26% to US$40.20

Price target increased by 7.8% to US$55.45

Recent updates

Ventyx Biosciences: Ready To Escape "The Crash Cycle"

Ventyx Biosciences, Inc. Presents New 52-Week Results from the Phase 2 Trial of VTX002 (Tamuzimod) in Ulcerative Colitis at UEG Week 2024

Ventyx Biosciences, Inc. announced that it expects to receive $26.99994 million in funding from Aventis Inc.

Ventyx Biosciences, Inc. announced that it expects to receive $26.99994 million in funding from Aventis Inc.

Ventyx Biosciences, Inc. Announces Executive Appointments

Ventyx Biosciences, Inc. Announces CFO Changes

Price target decreased by 10.0% to US$10.00

Price target increased by 9.8% to US$11.75

New major risk - Revenue and earnings growth

Ventyx Biosciences, Inc. Announces Results from the Phase 2 Trial of Vtx958 in Participants with Moderately to Severely Active Crohn’S Disease

Is Ventyx Biosciences (NASDAQ:VTYX) In A Good Position To Invest In Growth?

Ventyx Biosciences: Slim Chances In A Fat Market (Rating Downgrade)

Ventyx Biosciences, Inc. Announces Positive Preclinical Data for CNS-Penetrant NLRP3 Inhibitor VTX3232 Demonstrating Reversal of Obesity and Improvements in Cardiometabolic and Inflammatory Markers

Ventyx Biosciences Announces Appointment of Matthew Moore as Chief Operating Officer

New major risk - Revenue and earnings growth

Ventyx Biosciences, Inc. to Report Q1, 2024 Results on May 09, 2024

Ventyx Biosciences, Inc., Annual General Meeting, Jun 05, 2024

Price target increased by 13% to US$10.90

Ventyx Pivots To Obesity Amid Transformation

Ventyx Biosciences, Inc. Reports Clinical Data for Its NLRP3 Inhibitor Portfolio and Provides Pipeline Updates at Virtual Investor Event

Ventyx Biosciences, Inc. announced that it expects to receive $100.0073 million in funding

Bragar Eagel & Squire, P.C. Files Class Action Lawsuit Against Ventyx Biosciences, Inc. and Encourages Investors to Contact the Firm

Price target increased by 8.9% to US$9.67

New major risk - Revenue and earnings growth

Here's Why We're Watching Ventyx Biosciences' (NASDAQ:VTYX) Cash Burn Situation

Ventyx: Too Risky Right Now After Some Poor Data

Founder recently sold US$125k worth of stock

Founder notifies of intention to sell stock

Ventyx Biosciences, Inc. Announces Executive Changes

New major risk - Revenue and earnings growth

Price target decreased by 26% to US$40.20

Ventyx Biosciences Announces Positive Results from the Phase 2 Trial of VTX002 in Patients with Moderate-To-Severely Active Ulcerative Colitis

Chief Business Officer notifies of intention to sell stock

Companies Like Ventyx Biosciences (NASDAQ:VTYX) Are In A Position To Invest In Growth

President & Chief Medical Officer notifies of intention to sell stock

New minor risk - Share price stability

Ventyx Biosciences, Inc. to Report Q2, 2023 Results on Aug 10, 2023

Chief Financial Officer notifies of intention to sell stock

Chief Scientific Officer notifies of intention to sell stock

New minor risk - Share price stability

President & Chief Medical Officer notifies of intention to sell stock

Ventyx Biosciences, Inc. Announces Initiation of Dosing in A Phase 1 Trial of VTX3232, A Novel CNS-Penetrant NLRP3 Inhibitor

Ventyx Biosciences (NASDAQ:VTYX) Is In A Good Position To Deliver On Growth Plans

President & Chief Medical Officer exercised options and sold US$362k worth of stock

President & Chief Medical Officer exercised options and sold US$118k worth of stock

Ventyx Biosciences, Inc. to Report Q1, 2023 Results on May 11, 2023

Chief Financial Officer exercised options and sold US$968k worth of stock

Chief Financial Officer exercised options and sold US$207k worth of stock

Executive Chair exercised options and sold US$2.8m worth of stock

Price target increased by 7.8% to US$55.45

We're Not Very Worried About Ventyx Biosciences' (NASDAQ:VTYX) Cash Burn Rate

Price target increased by 7.6% to US$55.50

Independent Director exercised options and sold US$969k worth of stock

Ventyx Biosciences, Inc. Announces Board Appointments

Founder recently sold US$1.7m worth of stock

President & Chief Medical Officer exercised options and sold US$1.4m worth of stock

Chief Scientific Officer recently sold US$1.2m worth of stock

Chief Financial Officer exercised options and sold US$1.3m worth of stock

Founder recently sold US$8.7m worth of stock

Ventyx Biosciences, Inc Announces Dosing of the First Patient in the Phase 2 Serenity Trial of VTX958 for the Treatment of Moderate to Severe Plaque Psoriasis

High number of new directors

Ventyx Biosciences, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Ventyx Biosciences: Not Chasing This Rally

We Think Ventyx Biosciences (NASDAQ:VTYX) Can Afford To Drive Business Growth

Ventyx Biosciences, Inc. Announces Positive Data from its Phase 1 Single Ascending Dose and Multiple Ascending Dose Trial of VTX958, Novel and Selective Allosteric TYK2 Inhibitor

Ventyx Biosciences GAAP EPS of -$0.39 beats by $0.06

Ventyx Biosciences, Inc. to Report Q2, 2022 Results on Aug 15, 2022

Ventyx Biosciences Announces Positive Topline Phase 1 Data for Its Peripheral Nlrp3 Inhibitor Vtx2735

Ventyx Biosciences autoimmune/autoinflammatory candidate meets phase 1 goals